Senseonics : Corporate Presentation 09/09/2022

Eversense®

CGM System

The world's FIRST and ONLY long-term Continuous Glucose Monitoring System

Tim Goodnow, PhD	Corporate Presentation
President and CEO	August 2022

1

FORWARD-LOOKINGSTATEMENTS

Any statements in this presentation about future expectations, plans and prospects for Senseonics, including statements about patient benefits, perceptions, uptake of the Eversense E3 product, and the ability to introduce the product to additional patients, statements regarding future coverage decisions and final outcomes, statements concerning Senseonics' product pipeline and future product enhancements, and other statements containing the words "believe,""expect," "anticipate", "intend," "may," "projects," "will," "planned," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of

1995. These forward-looking statements are based on management's current expectations and projections about future events, and such statements are, by their nature

subject to uncertainties.

The risks and uncertainties that may cause actual results, levels of activity, performance or achievements to differ materially from the Company's current expectations include uncertainties related to the commercial launch and commercial expansion of the Eversense product, uncertainties inherent in the transition of commercialization responsibilities to Ascensia Diabetes Care and its commercial initiatives, uncertainties in insurer, regulatory and administrative processes, decisions and policy

determinations, the risks attendant to the launch and commercialization of a new product in a competitive market, the availability of capital to fund the Company's continued operations and execute its business plan, and such other factors that are more fully described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission ("SEC") on March 1, 2022, the Company's Quarterly Report on

Form 10-Q for the quarter ended June 30, 2022, as filed with the SEC on August 9, 2022, and its other filings with the SEC. Statements made in this presentation speak only as of the date of this presentation and should not be relied upon as of any subsequent date, and the Company assumes no obligation to update any such forward- looking statements, whether as a result of new information, future events or otherwise, except as required by law.

2

OUR MISSION

To transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology.

3

CORPORATE OVERVIEW AND MILESTONES

The FIRST and ONLY long-term and implantable CGM System. Available by prescription in US and select markets in Europe. Proven technology with rich development history, regulatory approvals and commercial accomplishments.

2016 - 2017

2018

2019

2020

2021

2022

Eversense®	Eversense®
System (90-day)	System (90-day)
Eversense® XL	Expanded HCP
System (180-day)	certification
	to Nurse
	Practitioners (NPs)
	and Physician
	Assistants (PAs)

NOTE: Items in blue are based on a number of risks and assumptions.

MRI compatibility	NEW Eversense
Therapeutic	180-day sensor
(non-adjunctive)	PMA supplement
indication	submitted

Expanded HCP	NEW Eversense
certification to include	180-day sensor
non physicians	submitted
	Achieved 200M
	Covered Lives
	Executed
	Commercial
	Collaboration
	Agreement with
	Ascensia Diabetes
	Care (ADC)

Feb. 1 OUS ADC Transition

April 1 US ADC

Transition

Secured 175M in net proceeds

NEW Eversense E3 180-day sensor approval

NEW Eversense E3 180-day sensor approval

365-day Pivotal Trial Initiated

4

HIGH GROWTH MARKET

CGM Fastest Growing Diabetes Technology Segment Globally*

	CGM Global Market Size			$8.2
		~ 37% CAGR				$14B+
($)				$7.1
Billions			$5.6			Annual US
in						Market
Revenue		$4.3
				Opportunity
	$2.7
$1.7
						*Estimates for top 4 CGM companies (Dexcom, Abbott, Medtronic and
2017	2018	2019	2020	2021	2022E	Senseonics), based upon available publicly stated guidance, historic
performance, and external CGM market models.

Estimated U.S. CGM Penetration, ~40% US Type 1 & ~25% US IIT

*Company reports, company and analyst estimates.

5